BioVie Invited to Present Data on Bezisterim in Parkinson’s Disease at the AD/PD2027 International Conference on Alzheimer's & Parkinson’s Diseases

Clinically meaningful improvement on the trial’s composite measure occurred in 25% of bezisterim patients versus 4% with placebo.

Rhea-AI Summary

BioVie (NASDAQ: BIVI) will present bezisterim Parkinson’s disease findings in two oral presentations at the AD/PD2027 conference on March 20, 2027. The Barcelona presentations will cover additional findings from SUNRISE-PD, a randomized, double-blind, placebo-controlled trial involving 57 patients treated for 12 weeks.

In the overall modified intent-to-treat population, clinically meaningful improvement on the Composite Benefit Score, a measure combining several disease domains, occurred in 25% versus 4% with placebo; clinically meaningful worsening occurred in 14% versus 46%. A prespecified subgroup with higher baseline platelet counts showed statistically significant improvements versus placebo in non-motor, motor and total disease-rating scores.

6 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

How the balance works

Positive

• Moderate pointComposite Benefit Score favored bezisterim in the overall modified intent-to-treat population; Cohen’s d = -1.61, p=0.0004.
• Minor pointClinically meaningful composite-score improvement occurred in 25% with bezisterim versus 4% with placebo, a 6.25-fold likelihood.
• Minor pointClinically meaningful composite-score worsening occurred in 14% with bezisterim versus 46% with placebo; relative risk 0.30.
• Minor pointNon-motor scores improved in the prespecified higher-platelet subgroup: -1.62 versus +1.86 with placebo; p=0.0124.
• Minor pointMotor scores improved in the prespecified higher-platelet subgroup: -1.32 versus +1.26 with placebo; p=0.0265.
• Minor pointTotal disease-rating scores improved in the prespecified higher-platelet subgroup: -1.23 versus +1.21 with placebo; p=0.0006.

Negative

• None.

Key Figures

Trial participants: 57 patients Platelet-count subgroup threshold: >230 × 10⁹/L MDS-UPDRS Part I: -1.62 vs. +1.86; p=0.0124 +5 more

Trial participants

57 patients

Randomized SUNRISE-PD trial

Platelet-count subgroup threshold

>230 × 10⁹/L

Prespecified higher-inflammation subgroup

MDS-UPDRS Part I

-1.62 vs. +1.86; p=0.0124

Bezisterim vs. placebo in the prespecified subgroup

MDS-UPDRS Part III

-1.32 vs. +1.26; p=0.0265

Bezisterim vs. placebo in the prespecified subgroup

MDS-UPDRS total score

-1.23 vs. +1.21; p=0.0006

Bezisterim vs. placebo in the prespecified subgroup

Composite Benefit Score

Cohen’s d=-1.61; p=0.0004

Treatment effect favored bezisterim in the overall modified intent-to-treat population

Clinically meaningful improvement

25% vs. 4%

Bezisterim vs. placebo on the Composite Benefit Score

Clinically meaningful worsening

14% vs. 46%

Bezisterim vs. placebo

Historical Context

1 past event · Latest: Oct 20

1 event

1. Oct 20

   clinical data

   24h Move

   -9.5%

   Reported SUNRISE-PD subgroup improvements and favorable Composite Benefit Score findings in early Parkinson’s disease.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

double-blind, placebo-controlled, mds-updrs, modified intent-to-treat, +1 more

5 terms

double-blind medical

"57-patient randomized, double-blind, placebo-controlled SUNRISE-PD trial"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"randomized, double-blind, placebo-controlled SUNRISE-PD trial"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

mds-updrs medical

"Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)"

A clinician-rated scorecard used to measure the severity and progression of Parkinson’s disease symptoms, covering movement problems, daily activities and other related issues. Investors use changes in this score during clinical trials as a clear, standardized signal of a drug’s effectiveness—similar to a report card showing whether a treatment meaningfully improves patients’ lives, which can influence regulatory approval, market expectations and a company’s valuation.

modified intent-to-treat medical

"In the overall modified intent-to-treat population"

A modified intent-to-treat (mITT) population is a version of a clinical trial analysis that includes most but not all people who were originally randomized, typically excluding those who never received the study treatment or lacked key baseline data. For investors, mITT matters because it can change how effective or safe a drug appears compared with a strict all-randomized analysis; thinking of it like judging a recipe only from cooks who actually made the dish helps explain how the choice of who is counted can shift results and influence regulatory and market reactions.

pharmacodynamic endpoint medical

"The primary pharmacodynamic endpoint was to assess the effect of bezisterim"

A pharmacodynamic endpoint is a measurable biological effect used in a clinical study to show that a drug is hitting its intended target or producing a expected physiological response. It can be a lab value, a biomarker level, a change in a tissue or organ function, or a clinical sign directly linked to the drug's mechanism of action; unlike safety endpoints, it is chosen to demonstrate drug activity or proof of concept rather than to detect harm. Pharmacodynamic endpoints do not by themselves prove clinical benefit (improved symptoms or outcomes) but are used to support dose selection, mechanism validation, and early efficacy hypotheses.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARSON CITY, Nev., Nov. 10, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the Company has been invited to present two oral presentations at the AD/PD2027 International Conference on Alzheimer's & Parkinson’s Diseases to be held in Barcelona, Spain from March 16-20, 2027.

The two presentations will be shared during the “AD, PD and Lewy Body Disorders: Novel Therapies” session being held on Saturday, March 20.

Presentation 1

• Title: Exploratory Analyses of a Phase II Trial (SUNRISE-PD) Suggest Positive Effects of Bezisterim on Markers of Parkinson’s Disease Progression

• Presenter: Joseph M. Palumbo, MD, BioVie Inc.

• Time:  9:10–9:25 a.m.
  
  

Presentation 2

• Title: Efficacy of Bezisterim in Early Parkinson's Disease: Clinical Outcomes and Biomarker-Based Patient Selection in the Phase 2 SUNRISE-PD Trial

• Presenter: Suzanne Hendrix, PhD, CEO of Pentara Corporation

• Time:  9:25–9:40 a.m.
  
  

The presentations will share additional findings from the 57-patient randomized, double-blind, placebo-controlled SUNRISE-PD trial (NCT06757010). Patients received bezisterim or placebo for 12 weeks. The study assessed motor symptoms, non-motor symptoms, activities of daily living, sleep, inflammatory biomarkers, and overall clinical benefit using a Composite Benefit Score (CBS), a fit-for purpose measure designed to capture changes across multiple domains of Parkinson's disease.

Patients with higher systemic inflammation at the start of the trial – defined as above-median platelet counts above 230 × 10⁹/L – demonstrated the strongest response to bezisterim. In this prespecified subgroup, which represents approximately half of the trial population, bezisterim-treated patients experienced significant improvements in the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part I (non-motor) scores (-1.62 vs. +1.86 for placebo; Cohen’s d = -1.33; p=0.0124), Part III (motor) scores (-1.32 vs. +1.26; Cohen’s d = -0.92; p=0.0265), and Total Scores (-1.23 vs. +1.21; Cohen’s d = -1.45; p=0.0006).

“These results provide evidence that an anti-inflammatory treatment can benefit both motor and, importantly, non-motor symptoms of Parkinson’s disease,” said Clarence Ahlem, BioVie’s Senior Vice President and Program Lead for Parkinson’s Disease. “Because non-motor symptoms remain a significant unmet need, the breadth of activity observed with bezisterim is particularly encouraging for its development as a treatment for early Parkinson’s disease. In SUNRISE-PD we observed a consistent pattern of improvement across motor symptoms, non-motor symptoms, and daily functioning, with particularly encouraging results among patients with higher baseline platelet counts, a potential marker of systemic inflammation. We believe these findings provide an important foundation for future studies and support the development of bezisterim as a treatment with the potential not only to provide symptomatic benefit, but also to impact the underlying disease process and potentially slow disease progression.”

In the overall modified intent-to-treat population, efficacy outcomes generally favored bezisterim across multiple measures. The CBS also demonstrated a large treatment effect favoring bezisterim (Cohen’s d = -1.61; p=0.0004). Patients receiving bezisterim were 6.25-fold more likely to achieve clinically meaningful improvement on the CBS than patients receiving placebo (25% vs 4%), corresponding to a 525% relative increase and a 21-percentage-point absolute difference. Conversely, the risk of clinically meaningful worsening was approximately 70% lower with bezisterim than with placebo (14% vs 46%; relative risk 0.30), representing a 32-percentage-point absolute risk reduction.

About Parkinson’s Disease

Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide, affecting more than 10 million people, including an estimated 1.1 million people in the United States, with nearly 90,000 new diagnoses each year.¹

PD is best known for motor symptoms such as tremor, rigidity, slowed movement, and postural instability. However, PD involves neurodegeneration beyond the areas of the brain primarily associated with movement, giving rise to a broad range of non-motor symptoms, including sleep disturbances, cognitive changes, depression, anxiety, fatigue, and autonomic dysfunction.²

Some non-motor symptoms may emerge years before a diagnosis of PD³ and can be more troublesome and disabling than movement symptoms.⁴ Non-motor symptoms are strongly associated with reduced quality of life, yet they remain frequently under-recognized and undertreated.⁵˒⁶

The economic burden of Parkinson's disease and atypical parkinsonism in the United States was estimated at $82.2 billion in 2024, including $58.4 billion in indirect and non-medical costs, and is projected to reach $112.4 billion annually by 2045. There remains a substantial need for treatments and care that address both the motor and non-motor manifestations of PD.

About the SUNRISE-PD trial

SUNRISE-PD (NCT06757010) was a Phase 2b, multicenter, randomized, double-blind, placebo-controlled trial designed to establish proof-of-mechanism and proof-of-concept in early-stage Parkinson’s disease (PD) patients naïve to treatment with symptomatic dopaminergic therapy (carbidopa/levodopa). The study leveraged a hybrid decentralized design that lasted 20 weeks from the initial screening phase, a 12-week treatment period, through to the safety follow up.

Following a screening and prospective clinical stability assessment period, 57 eligible participants were randomized 1:1 to receive either 20 mg of bezisterim or matching placebo twice daily for 12 weeks.

The study prospectively evaluated a predefined battery of biologic, clinical, and quality of life assessments to assess a series of motor and non-motor endpoints and evaluate signals consistent with bezisterim’s expected metabolic and anti-inflammatory actions. The trial endpoints and planned analyses were prespecified in the final Statistical Analysis Plan (SAP) submitted to the FDA prior to data unblinding.

The primary pharmacodynamic endpoint was to assess the effect of bezisterim on hematologic inflammatory biomarker indices (MLR, SIRI, NLR, SII, PLR, AISI) and a composite of those markers. Secondary and exploratory endpoints aimed to understand the pharmacodynamic, clinical, safety and tolerability, and to define the profile of bezisterim versus placebo in the study population to design a potentially pivotal registrational Phase 3 trial.

The study was designed to reduce common barriers to participation in PD research, including delayed diagnosis, limited mobility, geographic constraints, and access to specialized care, and allowed patients to participate either from their home or at a clinical site. At-home participants were visited by study nurses who administered a modified MDS-UPDRS Part III and standard Part I and II examinations under the supervision of a physician and MDS-UPDRS expert attending through live video link. The Part III exam was recorded for review and scoring by a central rating committee with a final expert rater review and adjudication.

About Bezisterim

Bezisterim (NE3107) is an investigational oral drug that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NFκB, TNFα), bezisterim may have therapeutic potential in several disease indications, including Parkinson’s disease (PD), Long COVID (LC), and Alzheimer’s disease (AD).

In PD, BioVie completed the SUNRISE-PD trial, which enrolled 57 patients to establish proof of mechanism and proof of concept in individuals with early-stage disease who had not previously been treated with carbidopa/levodopa. Topline results showed that patients treated with bezisterim experienced improvements with blood-based markers of inflammation, as well as a broad range of biomarkers associated with cellular health and neuronal integrity. Clinically, patients treated with bezisterim demonstrated greater improvements than those receiving placebo across multiple measures of daily functioning, motor symptoms, and non-motor symptoms.

For LC, the ADDRESS-LC trial enrolled approximately 200 patients to evaluate whether bezisterim may help reduce brain fog, fatigue, and other lingering neurological symptoms associated with LC. The hypothesis being studied is that these symptoms may be triggered by persistent circulation of spike protein fragments that trigger inflammation via NFκB activation (which bezisterim has been shown to modulate).

In AD, BioVie has conducted Phase 2 and Phase 3 trials. Preliminary data from these trials suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a therapy for the six million Americans living with AD.

About BioVie Inc.

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead investigational drug candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer’s and Parkinson’s disease. Bezisterim is also being studied for Long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue.

In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites. For more information, visit www.bioviepharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate," "intend," "plan," "believe," "seek," "estimate," "will," "project," “potential,” “may,” or words of similar meaning. Forward-looking statements in this release include, but are not limited to, statements regarding: the potential for bezisterim to address unmet clinical needs in Long COVID and Parkinson’s disease; the design and conduct of future clinical trials, including a potentially pivotal Phase 3 trial; the potential clinical significance of subgroup analyses and biomarker observations; and the Company’s ability to advance bezisterim through clinical development. The clinical endpoints reported in this release are exploratory in nature. The Phase 2 ADDRESS-LC trial did not achieve statistical significance on any endpoint in the overall intent-to-treat population; statistically significant results were observed only in pre-specified subgroup analyses. Subgroup analyses are hypothesis-generating and may not be replicated in future trials. Changes in biomarkers may not correlate with clinical benefit or support regulatory approval. The FDA has not validated these endpoints as surrogate endpoints for Long COVID. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to risks related to the early stage of development of bezisterim and other product candidates, the possibility that results observed in this Phase 2 study of 203 patients may not be replicated in larger or longer-duration trials, the exploratory nature of subgroup analyses, the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, the possibility that clinical trial results may not be indicative of results in subsequent or larger trials, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

For Investor Relations Inquiries:

Contact:
Chuck Padala
Managing Director, LifeSci Advisors, LLC
chuck@lifesciadvisors.com

For Media Inquiries:

Contact:
Melyssa Weible
Managing Partner, Elixir Health Public Relations
mweible@elixirhealthpr.com

¹  Parkinson's Foundation. Statistics. Accessed July 16, 2026.
²  Peña-Zelayeta et al. J Pers Med. 2025;15(5):172. doi:10.3390/jpm15050172.
³  Castilla-Cortázar et al. J Transl Med (2020) 18:70. https://doi.org/10.1186/s12967-020-02223-0
⁴  Parkinson's Foundation. Non-movement symptoms. Accessed July 16, 2026.
⁵  van der Meer et al. Expert Rev Pharmacoecon Outcomes Res. 2025;25(1):17–27. doi:10.1080/14737167.2024.2390042.
⁶  Chaudhuri et al. Parkinsonism Relat Disord. 2015;21(3):287–291. doi:10.1016/j.parkreldis.2014.12.031.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioVie’s SUNRISE-PD trial show for bezisterim?

Clinically meaningful improvement on the Composite Benefit Score occurred in 25% of bezisterim patients versus 4% with placebo in the overall modified intent-to-treat population. Clinically meaningful worsening occurred in 14% versus 46%. The randomized, double-blind, placebo-controlled trial enrolled 57 patients and included 12 weeks of treatment.

How was the higher-inflammation subgroup defined in BioVie’s SUNRISE-PD trial?

The prespecified subgroup had baseline platelet counts above 230 × 10⁹/L, the trial’s above-median threshold for higher systemic inflammation. It represented approximately half of the trial population and showed statistically significant improvements versus placebo in non-motor, motor and total disease-rating scores.

What was the primary endpoint of BioVie’s SUNRISE-PD trial?

The primary endpoint assessed bezisterim’s effect on blood-based inflammatory biomarker indices and a composite of those markers. Secondary and exploratory endpoints examined clinical effects, safety and tolerability to help design a potentially pivotal Phase 3 trial. Endpoints and planned analyses were prespecified before the treatment assignments were revealed.